Skip to content

Evaluation of the Impact of Different Retzius-Sparing Approaches in Radical Prostatectomy on Postoperative Urinary Control Recovery and Related Pelvic Floor Structures Based on Pelvic Floor Functional MRI: A Prospective, Three-Arm, Open-Label, Randomized Controlled Trial

Evaluation of the Impact of Different Retzius-Sparing Approaches in Radical Prostatectomy on Postoperative Urinary Control Recovery and Related Pelvic Floor Structures Based on Pelvic Floor Functional MRI: A Prospective, Three-Arm, Open-Label, Randomized Controlled Trial - Randomized Controlled Trial Evaluating the Impact of Different Retzius-Sparing Techniques on Postoperative Urinary Continence and Pelvic Floor Structure Recovery After Radical Prostatectomy Using Pelvic Functional MR

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500111620
Enrollment
Unknown
Registered
2025-11-03
Start date
2025-11-10
Completion date
Unknown
Last updated
2025-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Group A:Robot-Assisted Laparoscopic Traditional Anterior Approach Nerve-Sparing Radical Prostatectomy
Group B:robot-assisted laparoscopic posterior approach retzius-sparing nerve-sparing radical prostatectomy
Group C:robot-assisted laparoscopic anterior approach retzius-sparing nerve-sparing radical prostatectomy

Sponsors

The First Medical Center of Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Pathologically confirmed localized prostate cancer (cT1-2N0M0); 2. Age <= 80 years; 3. Intermediate to low-risk patients based on D'Amico risk stratification: PSA 4-20 ng/ml, Gleason score <= 7, T2b or lower; 4. Patient agrees to randomization and signs the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Preoperative urinary incontinence or neurogenic bladder; 2. History of pelvic or urethral radiotherapy, chemotherapy, surgery, or endocrine therapy; 3. Imaging suggesting suspected lymph node or bone metastasis; 4. Severe cardiopulmonary diseases that cannot tolerate surgery; 5. Presence of metal implants or any condition preventing tolerance of MRI; 6. Patients whom the investigator deems unsuitable for participation in this clinical trial.

Design outcomes

Primary

MeasureTime frame
immediate urinary control recovery rate;

Secondary

MeasureTime frame
long-term urinary control recovery rate;pelvic functional MRI-related parameters;progression-free survival;surgical margin;

Countries

China

Contacts

Public ContactBaojun Wang

Department of Urology, Medical Division, Third Medical Center, PLA General Hospital

jzzhale@163.com+86 135 2190 8910

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026